Viral immunotherapy drug compound and purpose thereof

A technology of immunotherapy drugs and antiviral drugs, applied in the field of biomedicine, can solve the problems of ineffective improvement of primary immune response, GM-CSF cannot provide adjuvant activity, etc., to prevent re-infection, easy to promote, and enhance immune response Effect

Inactive Publication Date: 2015-02-11
FUDAN UNIV
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hasan et al found that GM-CSF cannot provide significant adjuvant activity by intramuscularly injecting GM-CSF immediately before

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Viral immunotherapy drug compound and purpose thereof
  • Viral immunotherapy drug compound and purpose thereof
  • Viral immunotherapy drug compound and purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Unless otherwise specified, the experimental data in the examples of the present invention are the average values ​​obtained from each mouse in each group. Example 1: The immunization strategy of GM-CSF combined with recombinant hepatitis B vaccine enhances the immune response of C57BL / 6 to recombinant hepatitis B subunit vaccine

[0063] Materials and Instruments:

[0064] Experimental materials: Genetic engineering (CHO) hepatitis B vaccine [Recombinant Hepatitis B Vaccine (CHO)], 10ug / 1.0mL, recombinant human granulocyte macrophage colony-stimulating factor for injection [Recombinant Human Granulocyte / Macrophage Clolony-Stimulating Factor for Injection], 300ug / support, CHO-expressed genetically engineered hepatitis B vaccine stock solution (HBsAg stock solution) were provided by North China Pharmaceutical Group Jintan Biotechnology Co., Ltd.

[0065] Main kits and instruments: RPMI1640 culture medium (WISENT company); fetal bovine serum (Tianjin Haoyang Biological P...

Embodiment 2

[0131] Example 2: The immunization strategy of GM-CSF combined with recombinant hepatitis B vaccine breaks the immune tolerance of HBsAg transgenic mice and induces anti-HBsAg humoral immune response in transgenic mice

[0132] Materials and Instruments:

[0133] HBsAg transgenic mice (C57BL / 6J-Tg(AlblHBV)44Bri / Jf4J) were purchased from Shanghai Public Health Clinical Center affiliated to Fudan University. "Hepatitis B surface antigen enzyme-linked immunoassay diagnostic kit" and hepatitis B surface antigen standard were purchased from Beijing Jinhao Pharmaceutical Co., Ltd. Other experimental materials, main reagents and instruments are the same as in Example 1.

[0134] experiment method:

[0135] Animal grouping and immunization methods:

[0136] 35 HBsAg transgenic mice (C57BL / 6J-Tg(AlblHBV)44Bri / Jf4J) (initial serum HBsAg concentration is 5000-10000pg / ml), were randomly divided into 5 groups, 7 mice in each group, and the experimental grouping was performed according ...

Embodiment 3

[0157] Example 3: GM-CSF Combined with Recombinant Hepatitis B Vaccine Immune Strategy Breaks Immune Tolerance of HBsAg Transgenic Mice Induces Anti-HBsAg Cellular Immune Response in Transgenic Mice and Eliminates HBsAg in Liver

[0158] Materials and Instruments:

[0159] HBsAg transgenic mice (C57BL / 6J-Tg(AlblHBV)44Bri / Jf4J) were purchased from Shanghai Public Health Clinical Center affiliated to Fudan University. The primary antibody and secondary antibody of hepatitis B surface S antigen immunohistochemistry were purchased from Shanghai Changdao Biotechnology Co., Ltd. Other experimental materials, main reagents and instruments are the same as in Example 1.

[0160] Animal grouping and immunization methods:

[0161] Thirty-five HBsAg transgenic mice (C57BL / 6J-Tg(AlblHBV)44Bri / Jf4J) (initial serum HBsAg concentration was 5000-10000pg / ml) were randomly divided into 5 groups with 5 mice in each group. The experimental groups are shown in the table below. Each group of vacc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention involves a new viral immunotherapy drug complex, and in particular, a viral immunotherapy drug complex for persistent hepatitis B infection. The present drug consists of antiviral drugs, immunoregulating drugs and a recombinant hepatitis B vaccine, for use in treating hepatitis B and in particular chronic hepatitis B infections. Antiviral drugs of the described drug complex are selected among α-IFN and nucleosides; the immunoregulating drugs are selected from among GM-CSF and similar.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a novel drug compound for virus immunotherapy. In particular, it relates to a drug compound for virus immunotherapy for persistent hepatitis B virus infection. Background technique [0002] The prior art discloses that hepatitis B is an infectious disease caused by hepatitis B virus (HBV), transmitted through blood and body fluids, and mainly based on liver damage. It is a serious public health problem, and the disease is harmful to human health. The threat is great. Studies have shown that after infection with hepatitis B, some patients will develop into a state of chronic persistent infection, which may evolve into liver cirrhosis or primary hepatocellular carcinoma. my country is a high prevalence area of ​​hepatitis B virus infection. About 350,000 people die of hepatitis B-related diseases (such as liver cirrhosis and liver cancer) every year. Among them, the infection rate of the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K39/29A61K39/39A61P31/20A61P1/16
CPCA61K2039/55522A61K2039/545A61K45/00C12N2730/10134A61K39/39A61K39/292A61K38/193A61K38/21A61K31/513A61K31/522A61K31/675A61K31/7072A61K45/06A61K39/12A61K2300/00A61K47/60A61K38/212A61P1/16A61P31/20A61P37/04A61P43/00C12N7/00
Inventor 王宾王宪政张继明
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap